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 92 
Abstract  93 
Since 2010, the World Health Organization recommends that all suspected cases of malaria be 94 
confirmed with parasite-based diagnosis before treatment. These guidelines represent a paradigm 95 
shift away from presumptive antimalarial treatment of fever. Malaria rapid diagnostic tests (mRDTs) 96 
are central to implementing this policy, intended to target artemisinin-based combination therapies 97 
(ACT) to patients with confirmed malaria and to improve management of patients with non-malarial 98 
fevers. The ACT Consortium conducted ten linked studies, eight in sub-Saharan Africa and two in 99 
Afghanistan, to evaluate the impact of mRDT introduction on case management across settings that 100 
vary in malaria endemicity and healthcare provider type. This synthesis includes 562,368 outpatient 101 
encounters (study size range 2400 to 432,513). mRDTs were associated with significantly lower ACT 102 
prescription (range 8-69% versus 20-100%). Prescribing did not always adhere to malaria test results; 103 
in several settings ACTs were prescribed to more than 30% of test-negative patients or to fewer than 104 
80% of test-positive patients. Either an antimalarial or an antibiotic was prescribed for more than 105 
75% of patients across most settings; lower antimalarial prescription for malaria test-negative 106 
patients was partly offset by higher antibiotic prescription. Symptomatic management with 107 
antipyretics alone was prescribed for fewer than 25% of patients across all scenarios. In community 108 
health worker and private retailer settings, mRDTs increased referral of patients to other providers. 109 
This synthesis provides an overview of shifts in case management that may be expected with mRDT 110 
introduction and highlights areas of focus to improve design and implementation of future case 111 
management programs. 112 
 113 
 114 
 115 
116 
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 117 
Introduction 118 
Providing appropriate antimalarial treatment to patients who have malaria has been a long-119 
standing challenge in fever case management, and has traditionally relied on presumptive symptom-120 
based diagnosis. Many people with malaria do not receive effective antimalarial medications, 121 
increasing their risk of severe disease or death. At the same time, many of those who receive 122 
antimalarials do not have malaria and are suffering from a non-malaria illness which may need 123 
alternative treatment.1 In order to improve rational use of artemisinin-based combination therapies 124 
(ACTs), the World Health Organization (WHO) recommended in 2010 that all suspected cases of 125 
malaria should have parasitological confirmation before treatment.2, 3 These changes represent a 126 
paradigm shift from presumptive antimalarial treatment of fever to targeted use of ACTs only for 127 
those with a positive malaria test. 128 
Central to implementing this policy change are malaria rapid diagnostic tests (mRDTs), 129 
relatively simple, inexpensive and reliable point-of-care tests that can be used where high-quality 130 
microscopy services are not available.4 mRDTs are intended to improve the management of 131 
suspected malaria cases, increasing the use of first-line antimalarials in patients with confirmed 132 
malaria and encouraging the diagnosis and appropriate treatment of patients without malaria.1 133 
Following the WHO policy change, mRDT procurement has surged from 45 million tests globally in 134 
2008 to 314 million in 2014.5 Parasite-based diagnosis prior to treatment is now policy in public 135 
health facilities in most malaria-endemic countries, and mRDTs are also being introduced among 136 
private retail and community health providers.6, 7, 8, 9, 10, 11, 12, 13, 14  137 
Clinical trials and early pilot projects prior to the widespread adoption of mRDTs supported 138 
their use, though with some heterogeneity of results.15 Compared to presumptive treatment with 139 
antimalarials, case management based on mRDTs generally reduced antimalarial prescription, 140 
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particularly in settings with relatively high provider adherence to test results and low malaria 141 
prevalence.16, 17, 18, 19, 20, 21, 22 On the other hand, although provider adherence to negative mRDT 142 
results was high in some studies,16, 17, 23, 24 it was low in others.25, 26, 27 Comparable data from good-143 
quality studies in a variety of contexts are needed in order to anticipate the effects of mRDT 144 
implementation as these tests are rolled out at scale. 145 
The ACT Consortium is a research partnership created to address key questions and inform 146 
policy on ACT delivery.28 The Consortium conducted studies in ten countries in Africa and Asia, 147 
including ten studies specifically designed to address questions on improving the targeting of ACTs 148 
through the use of mRDTs. These studies looked at the impact of mRDT introduction on fever case 149 
management across a range of clinical and epidemiological contexts and among various types of 150 
health care provider. Studies evaluated different mRDT intervention packages, leading to 151 
heterogeneity that precludes formal meta-analysis. The current synthesis compares individual study 152 
results to identify patterns across contexts and provide an overview of what may be expected from 153 
mRDT implementation programs.154 
Methods 155 
Studies included in the analysis 156 
ACT Consortium studies were included in this analysis if they collected data on patient 157 
consultations for suspected malaria, evaluated an intervention to implement mRDTs by health care 158 
providers, and included a comparison group without the mRDT intervention. The ten studies 159 
meeting these criteria are described in Table 1, including the abbreviation for each study used 160 
throughout the text. All studies received ethical approval from their host academic institutions and 161 
national authorities; see open-access publications for further details.29, 30, 31, 32, 33, 34, 35, 36, 37 (Leslie, T. 162 
et al, in preparation) Data are available at the ACT Consortium data repository 163 
(https://actc.lshtm.ac.uk/) or from the authors on request. 164 
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Eight studies took place in sub-Saharan Africa and two in Afghanistan, in a mix of rural and 165 
urban settings. mRDTs were introduced in health facilities only (Afgh1, Cam1, Ghan1, Tanz1, Tanz2, 166 
Uga1), among community health workers (Afgh2, Uga2), in private drug shops only (Uga3), or in a 167 
combination of public facilities, private pharmacies, and drug shops (Nige1). Seven studies were 168 
cluster-randomized trials of interventions to introduce mRDTs, two studies were individually-169 
randomized trials (Afgh1, Ghan1), and one study was a descriptive “before and after” evaluation 170 
(Tanz1). All patients that were eligible in each study were included in the present analysis; typically 171 
these were patients with suspected malaria, although one study included only children under age 172 
five years (Uga2), and two studies collected data on all patient consultations (Tanz2, Uga1). Data 173 
were collected using provider-completed records of treatments administered (Afgh1, Afgh2, Ghan1, 174 
Uga1, Uga2), patient exit interviews (Tanz1), both of these methods (Cam1, Nige1, Tanz2), or 175 
provider-completed records with follow-up interviews of a subsample of patients (Uga3). 176 
From each study, “settings” and “scenarios” were identified for this analysis. Six studies 177 
were conducted in multiple settings (indicated by suffix a, b, c), such as distinct geographical areas 178 
and malaria transmission zones (Afgh1, Afgh2, Cam1, Tanz1, Uga2) or where providers used different 179 
methods of routine malaria diagnosis (presumptive care or microscopy; Afgh1, Ghan1). Trial arms or 180 
comparison groups within a setting were termed scenarios. All settings included at least one 181 
scenario without mRDT interventions, and settings in three studies (Cam1, Nige1, Tanz2) included 182 
multiple mRDT intervention scenarios. In total, the ten studies were conducted in 18 settings, with 183 
18 scenarios without mRDT interventions and 24 scenarios with mRDT interventions. 184 
Data were collected concurrently from scenarios with and without mRDT interventions in 185 
seven studies. In three studies (Nige1, Tanz1, Tanz2) data from scenarios without mRDT 186 
interventions were collected before mRDT introduction. The scale of the interventions and their 187 
evaluations varied: for example, in Uga1 the intervention was implemented in ten health facilities, 188 
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and data were collected on 432,513 patient encounters in the study area; while Tanz1 evaluated a 189 
nationwide intervention, and data were collected from 3,456 patients. 190 
Microscopy was widely available in all settings in Cam1 and available at some higher-level 191 
facilities in Tanz1, particularly in the Tanz1/c scenario without mRDT interventions. The two 192 
individually randomized studies (Afgh1, Ghan1) took place both in settings where microscopy was 193 
the standard practice and in settings where malaria diagnosis was symptom-based. Microscopy 194 
services were non-existent or very limited in the other six studies (Afgh2, Nige1, Tanz2, Uga1, Uga2, 195 
Uga3). 196 
Indicators of interest 197 
To examine the impact of mRDTs on patient care, malaria testing and prescribing indicators 198 
were reviewed. Since the objective was to compare case management in areas with and without 199 
mRDT interventions, our first indicator of interest was the proportion of patients tested by the 200 
provider with any parasite-based diagnostic test (microscopy or mRDT). Prescribing indicators were 201 
the proportions of patients prescribed one or more of the following medicines: ACTs, non-ACT 202 
antimalarials, antibiotics (antibacterials), antifungals, antihelminthics and antipyretics. The 203 
proportion of patients referred to another health care provider was also reviewed.  204 
The ACT indicator was adjusted to account for malaria epidemiology and differences in first-205 
line antimalarial in two cases: In Afghanistan, P. vivax was treated with chloroquine and P. 206 
falciparum with ACT; in these settings, the proportion of patients prescribed any antimalarial is 207 
reported instead of ACT. In Nige1, prescription of SP and ACTs are reported for the scenario without 208 
mRDT interventions, while only ACTs are reported for the scenarios with mRDT interventions. This 209 
reflects a change in treatment between the 2009 scenario without mRDT interventions (when ACTs 210 
were recommended but not yet widely used) and the 2011 scenarios with mRDT interventions 211 
(when ACTs had largely replaced SP). 212 
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Analytical approach 213 
Descriptive statistics on the indicators of interest were calculated from each scenario. 214 
Estimates for each indicator were made for scenarios without mRDTs and those with mRDTs. 215 
Prescribing indicators were further stratified by result of the diagnostic test performed by the health 216 
care provider. Odds ratios and 95% confidence intervals for indicators of interest within each setting 217 
were calculated using logistic regression with robust standard errors to account for clustering by the 218 
primary unit of sampling or randomization (see Supplementary Tables). Formal meta-analysis was 219 
deemed inappropriate due to heterogeneity of interventions evaluated and study contexts. 220 
However, to aid comparisons between scenarios with and without mRDTs, the indicators of interest 221 
are presented as graphic point estimates by study arm. The analysis was conducted in STATA 14 222 
(STATA Corp LP, College Station, TX). Factors which may explain variations in mRDT use are 223 
examined with additional qualitative data sources elsewhere.38  224 
Results 225 
Proportion of patients tested  226 
More patients were tested in scenarios where mRDTs had been introduced (Figure 1 and 227 
Tables S1-S3). However, even with mRDTs available, the percentage of patients tested varied widely, 228 
with 50% or fewer patients tested in five settings (Nige1, Tanz1/a, Tanz1/b, Tanz2, Uga1), and nearly 229 
100% in others (Afgh2/a, Afgh2/b, Uga/2, Uga2/b, Uga3). The largest increases in proportion of 230 
patients tested were seen where mRDTs were introduced outside of health facilities (Afgh2, Uga2, 231 
Uga3). Similar proportions of children and adults were tested in most scenarios, but in Nige1, 232 
Tanz1/a, and Uga1 test uptake was slightly higher for young children than for older patients. The 233 
proportion of patients tested is not reported in Afgh1 or Ghan1, where patients were individually 234 
randomized to mRDTs or microscopy (Afgh1/a, Afg1/b, and Ghan1/a), and to mRDTs or symptom-235 
based diagnosis (Afgh1/c and Ghan1/b).  236 
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Patients were also tested with microscopy in Cam1 and, to a lesser extent, in Tanz1. In 237 
Cam1/a and Cam1/b, microscopy was common in all scenarios, and test use was not higher in 238 
scenarios with mRDT interventions. In scenarios without mRDT interventions, 80% of patients were 239 
tested with microscopy. In the four scenarios with mRDT interventions, 27% to 61% of patients were 240 
tested with microscopy and 17% to 52% with mRDT (71% to 81% tested overall). Of the three Tanz1 241 
settings, microscopy was most frequently used in the Tanz1/c scenario without mRDT interventions, 242 
where 29% of patients were tested with microscopy and 2% with mRDT; in the corresponding 243 
scenario with mRDT interventions, 8% were tested with microscopy and 63% with mRDT. 244 
Prescription of ACTs and other antimalarial medications 245 
Overall, mRDTs were associated with lower ACT prescribing (Figure 2a and Table S4). In 246 
10/13 African settings, mRDT scenarios had statistically significantly lower ACT prescriptions than 247 
scenarios without mRDT interventions. In two African settings, there was little difference between 248 
mRDT and non-mRDT scenarios: Uga1, a high-transmission area where a high proportion of patients 249 
required ACTs even after testing and Ghan1/a, where all non-mRDT patients were randomized to 250 
testing with microscopy. In Nige1, where levels of testing were very low, presumptive diagnosis of 251 
malaria was common even where mRDTs were available. Prescription of ACT or SP in the scenario 252 
without mRDT interventions was similar to prescription of ACT in the three mRDT intervention 253 
scenarios (around 50%). In 4/5 Afghanistan settings, prescription of any antimalarial was much lower 254 
in scenarios with mRDT interventions than without; the exception was Afgh1/b, where (similar to 255 
Ghan1/a) all non-mRDT patients were randomized to testing with microscopy, and where malaria 256 
transmission was low.  257 
Recorded prescription of non-ACT antimalarials (e.g. SP, quinine, oral artemisinin 258 
monotherapies, etc.) was generally uncommon, except in Afghanistan. In 11/13 African settings, 259 
non-ACTs were prescribed for fewer than 10% of patients both with and without mRDT interventions 260 
(data not shown). Prescription of non-ACT antimalarials was higher in Cam1/b (20.9% in the scenario 261 
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without an mRDT intervention and approximately 15% in the two scenarios with mRDT 262 
interventions) and in Nige1 (52.8% in the scenario without an mRDT intervention and approximately 263 
30% in the three scenarios with mRDT interventions).  264 
Overall, the finding of lower ACT prescription in scenarios with mRDT interventions was 265 
mostly due to malaria test-negative patients not receiving ACTs (Figures 2b-d and Table S5). Fewer 266 
than 30% of test-negative patients were treated with ACTs in most mRDT intervention scenarios; 267 
exceptions were Cam1/a and Cam1/b, and Ghan1/a and Ghan1/b, where ACTs were prescribed for 268 
39.2% to 49.1% of patients with negative malaria test results. There was no evident difference in this 269 
indicator by test type; in the Cam1/a and Cam1/b scenarios with mRDT interventions, ACTs were 270 
prescribed to 17.3% to 42.9% of microscopy test-negative patients and 15.6% to 45.9% of mRDT 271 
test-negative patients (data not shown). The percentages of malaria test-positive patients in 272 
scenarios with mRDT interventions who were prescribed ACTs ranged from 60.2% to 98.0% in 12/15 273 
settings with data for this indicator. Prescription of ACTs to test-positive patients was over 90% in six 274 
of these settings, but was just 60.2% to 81.2% in another six settings, with 69.4% to 96.2% 275 
prescribed any antimalarial. In Tanz1/a, where stock-outs of ACTs in public health facilities were a 276 
major problem, ACT prescribing for test-positive patients was 18.2%. In Afgh1/a and Afgh2/a, 99.5% 277 
and 82.7% of test-positive patients were prescribed any antimalarial.  278 
Prescription of antibiotics 279 
In contrast to reduced ACT prescribing, the mRDT interventions were associated with 280 
significantly more prescribing of systemic antibiotic (antibacterial) medications in seven settings 281 
(Afgh1/c, Afgh2/a, Tanz1/a, Tanz1/b, Tanz1/c, Tanz2, Uga3) (Figure 3 and Tables S6-S7). In scenarios 282 
with mRDT interventions, antibiotic prescribing patterns varied by mRDT result. In all settings except 283 
Nige1, 40.0% to 79.9% of patients who tested negative for malaria were prescribed antibiotics. 284 
Antibiotic prescription was similar in patients who were not tested. Among those with a positive 285 
malaria test result, fewer than 45% were prescribed antibiotics, with higher proportions in Cam1/a 286 
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and Cam1/b. Prescription of both an antimalarial and a systemic antibiotic (Fig 4a and Table S8) was 287 
relatively uncommon in all settings (<25% of patients, except in Cam1 and Afgh2/b) and was similar 288 
or lower in scenarios with mRDT interventions. In contrast, the prescription of either an antimalarial 289 
or an antibiotic medicine was high in all settings (more than 68%, except in Tanz1/a) and similar or 290 
lower in scenarios with mRDT interventions (Figure 4b and Table S9). Further details of antibiotic 291 
prescribing in ACT Consortium studies are presented elsewhere.39 292 
Prescription of other medicines 293 
Data were recorded on prescription of other anti-infectives in some study settings. 294 
Prescription of systemic antifungals (fluconazole, griseofulvin) was reported in five settings (Cam1/a, 295 
Cam1/b, Ghan1/a, Ghan1/b and Uga1); the proportion of patients prescribed these medicines across 296 
these settings was 2.6% or less (Table S10). Prescription of antihelminthics (albendazole, 297 
mebendazole) was recorded in 13 settings (all study settings except those in Afgh2, Tanz2, and 298 
Uga2); the proportion of patients prescribed these medicines ranged from 0.3% to 33.3%, which did 299 
not appear attributable to whether the scenarios had an mRDT intervention or not (Table S10). 300 
Prescription of antipyretic medicines alone, for symptomatic relief, without an antimalarial 301 
or an antibiotic, ranged from 0.3% to 23.7% across all scenarios, and was similar or higher with 302 
mRDT interventions except in Nige1 (Figure 4c and Table S11). Polypharmacy, defined as the 303 
prescription of three of more medicines, varied widely across settings (Figure 4d). However, in most 304 
settings polypharmacy was comparable with and without mRDT interventions, but was significantly 305 
lower with mRDT interventions in four settings (Afgh1/b, Afgh2/a, Afgh2/b, Cam2/b (Figure 4d and 306 
Table S12). 307 
Referral  308 
Figure 5 and Table S13 show the percentage of patients referred to another care provider or 309 
facility. Referral was generally low across study settings. However, referral was significantly higher 310 
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with mRDT interventions among community health workers, particularly in Uga2/a, Uga2/b, and 311 
Afgh2/b, and to a lesser extent in Uga3. Referral was uncommon (<5%) across all scenarios in studies 312 
in public health facilities. 313 
Discussion 314 
Providing appropriate treatment to patients who present with malaria-like symptoms 315 
remains a challenge in many endemic regions. This synthesis of data from ten ACT Consortium 316 
studies illustrates the impact of mRDTs on case management. The data represent 24 scenarios 317 
where mRDTs were introduced, compared with 18 scenarios without mRDT interventions. This 318 
synthesis found that mRDT interventions reduced prescription of first-line antimalarials across 319 
almost all settings, except where the tests were not often used. However, prescribing did not always 320 
reflect test results: across a range of scenarios, ACTs were prescribed for some mRDT-negative cases 321 
and, at least as concerning, ACTs were not prescribed for all mRDT-positive cases. The use of mRDTs 322 
also influenced other treatment decisions, notably resulting in an increase of antibiotic prescription 323 
especially for test-negative cases. Referral of patients to other health care providers was low across 324 
nearly all settings, with a few specific exceptions discussed below. 325 
What lessons can be learned from this synthesis, to inform expectations of programs that 326 
implement mRDTs at scale? While mRDTs generally improve malaria case management, alone they 327 
are not a panacea to solve the major challenge of effective fever management. Simply providing 328 
mRDTs is insufficient if health workers continue prescribing antimalarials to test-negative patients27, 329 
40 or if alternative treatments are not appropriate. The ACT Consortium studies evaluated a range of 330 
tailored and pre-tested elements as part of mRDT intervention strategies, such as enhanced provider 331 
training or community awareness activities.41, 42 Anecdotally, interventions designed with more 332 
intensive formative research led to greater reductions in ACT prescription for test-negative patients; 333 
but such prescribing remained inappropriately high (10-49%). 334 
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Furthermore, in five of the eight African studies included in this analysis, more than 20% of 335 
patients who tested positive for malaria at the point of care were not prescribed ACTs. Under-336 
treatment of malaria in settings where mRDTs have been implemented has been recognized in a 337 
small proportion of cases (less than 5%), with few exceptions.43, 44, 45 However, results of this 338 
synthesis suggest that under-treatment may be a more common problem than previously 339 
recognized. The six settings with high ACT prescription for test-positive patients varied in terms of 340 
malaria epidemiology, geography, and provider type; the same is true for the six settings with lower 341 
ACT prescription for test-positive patients. To date, research into the reasons for this phenomenon 342 
has been limited, although ACT Consortium study results presented elsewhere suggest that provider 343 
motivations, stability of ACT supplies and pre-existing antimalarial preferences account for some of 344 
this under-prescription.38 Missed or ineffective treatment of malaria presents a risk to patients; a 345 
balance between reducing unnecessary antimalarial use while ensuring ACTs are provided to all 346 
malaria-positive cases needs to be integrated in future research, training, and implementation 347 
programs. 348 
This synthesis highlights the fact that effecting change in one health care practice can have 349 
knock-on consequences for other practices. In many ACT Consortium studies, mRDT implementation 350 
was associated with a higher level of antibiotic prescription, particularly for malaria test-negative 351 
patients.39 The proportion of patients prescribed either an antimalarial or an antibiotic was high, for 352 
more than 75% of cases across most settings, and this was approximately similar in settings with and 353 
without mRDT interventions. This suggests that in the absence of other diagnostic options, 354 
presumptive antimalarial treatment may be exchanged for presumptive antibiotic treatment when 355 
mRDTs are introduced. Many patients with uncomplicated febrile illness are likely to improve with 356 
symptomatic management only (e.g. antipyretic), as noted in WHO case management guidelines;46, 47 357 
this approach was prescribed for just 0% to 24% of patients in ACT Consortium studies. 358 
Inappropriate use of antimicrobials is of increasing global concern due to rising resistance, which can 359 
result in longer illnesses, higher mortality, and increased treatment costs.48, 49 A more 360 
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comprehensive approach to case management is needed, rather than focusing on only a single 361 
diagnosis and medication (e.g. malaria mRDTs and ACTs), if unintended consequences are to be 362 
avoided.50 363 
Our data support the observation that introducing mRDTs may increase patient referral to 364 
other health care providers, particularly among community health workers and private retailers.10, 51 365 
In particular, when a malaria test is negative, alternative diagnoses must be considered; the clinical 366 
skills and diagnostic capacity to achieve this are limited among providers with less formal training, so 367 
that referral may be necessary for adequate case management. Overall, referral remained 368 
infrequent in ACT Consortium studies. Even when referral is recommended, patients are not always 369 
inclined or able to follow the recommendation.52, 53, 54 If current recommendations to scale up 370 
mRDTs in community and private health care settings are implemented, in order to improve referral 371 
practices in a way that is safe for individual patients, and without unduly burdening other parts of 372 
the health care system, the role of mRDTs will need to be better integrated into local pathways of 373 
treatment-seeking and care provision.55, 56, 57 374 
The observed shifts in case management practices have cost implications for health systems 375 
and for patients. When mRDTs lead to reductions in ACT use, there can be substantial savings in ACT 376 
costs. However, additional costs are incurred for mRDT implementation: the tests themselves, 377 
alternative treatments provided to mRDT-negative patients, additional referrals, and the activities 378 
required for mRDT introduction, such as training, supervision, communication campaigns and quality 379 
control. The overall cost impact in a given context will depend on several parameters, including the 380 
relative cost of ACTs and mRDTs, the amount of subsidy for each, the proportion of patients tested, 381 
the proportion who test positive, and provider adherence to test results. Analyses of the incremental 382 
economic cost per fever case managed has been published for four studies included in this synthesis. 383 
Where mRDTs were compared to microscopy (Afgh1, Ghan1, and Cam1), mRDTs were cost-saving or 384 
costs were similar in Afghanistan58, with an incremental provider cost per fever case managed 385 
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ranging from 0.20 to 1.11 USD in in Ghana59 and Cameroon60 (2011 USD). Where mRDTs were 386 
compared with clinical diagnosis, the incremental provider cost per fever case managed ranged from 387 
0.24 USD to 10.9 USD across different transmission levels and provider types in Afghanistan, Ghana, 388 
and Uganda (2011 USD).58, 59, 61 These incremental costs may be considered good value for money if 389 
they lead to sufficient improvements in health outcomes. A full consideration of cost-effectiveness 390 
would require costs from both health sector and household perspectives, extrapolation to final 391 
health outcomes such as cost per death or disability adjusted life year (DALY) averted, and sensitivity 392 
analyses to explore the impact of variation in prescribing and referral practices. Ideally a full analysis 393 
should also include the impact of malaria testing on enhancing malaria surveillance systems and 394 
resulting improvements in targeting of malaria interventions.  395 
The present analysis was subject to several limitations. Data were collected concurrently 396 
from scenarios with and without mRDT interventions in seven studies, while in the other three 397 
(Nige1, Tanz1, and Tanz2) data were collected before and after mRDT introduction (Table 1). In 398 
Nige1, the interval between the two data collection points corresponded with a shift in antimalarial 399 
use from SP to ACT; while ACT prescription decreased, any antimalarial prescription remained high 400 
(≥75%). In addition, some indicators varied in availability and precise definition across studies (see 401 
footnotes to Figures and Supplementary Tables.) For example, in Uga2, prescription of antibiotics 402 
and polypharmacy were not reported because community health workers were only permitted to 403 
dispense antimalarials and antipyretics. In Tanz1, data on medicines prescribed were not available 404 
from scenarios without mRDTs, so data on medicines dispensed were used for all Tanz1 scenarios. In 405 
designing the ACT Consortium studies and mRDT implementation packages, investigators sought to 406 
accommodate varied and transitioning contexts, while still obtaining data that could be compared 407 
across studies. This synthesis therefore did not aim to provide combined estimates of the size of 408 
effect of the impact of mRDTs (meta-analysis). Instead, comparison of findings from the individual 409 
studies identified clear patterns across diverse geographical, epidemiological, and health sector 410 
contexts, indicating both robustness and generalizability of the results.  411 
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In summary, evidence from ten ACT Consortium studies demonstrates that mRDT 412 
introduction can reduce prescription of ACTs. However, mRDTs are not an easy technological fix. 413 
Critically, challenges exist in ensuring that all patients who test positive for falciparum malaria are 414 
prescribed ACT; anything less endangers individual patients and the credibility of programs. It is also 415 
necessary to ensure that patients who test negative receive appropriate management, which may or 416 
may not include other antimicrobials. ACT Consortium studies were conducted between 2007 and 417 
2013, and since that time mRDT implementation programs continue to evolve. These combined 418 
results provide an overview of the generally positive shifts in case management that may be 419 
expected with mRDT introduction, and highlight issues that warrant particular attention in future 420 
work on point-of-care diagnosis and fever and malaria case management.421 
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